The pharma technology zone within CPhI China, P-MEC China focuses on equipment, machinery, packaging, analysis and technology, and is an integral part of Asia?s largest annual networking event for the pharmaceutical community. Held alongside CPhI China for pharmaceutical ingredients and APIs, ICSE for contract services and BioPh for biopharmaceutical solutions, P-MEC China is expected to attract over 20,000 visitors, including 7,000 from outside of China.
June 24, Shanghai New International Expo Centre
Providing an international platform for companies involved in an array of pharmaceutical production and analysis activities, P-MEC China is a highly targeted, pharma focused event, which brings together buyers and specifiers from more than 100 countries in conjunction with its collocated shows.
P-MEC has evolved in line with industry demand to include instrumental analysis, measuring and testing technology, materials testing, quality control, laboratory equipment as well as the traditional, large-scale capital equipment for which P-MEC is well known.
The domestic market in China for pharmaceuticals is already huge, yet it continues to grow, and there is an increasing need for high-value chemicals and contract services. There is also significant demand for innovative, high-quality equipment and machinery, particularly if it is ISO certified.
With all fields of the pharma industry gathered under one roof, and an extended conference programme, all the ingredients of success will be there. Join us at P-MEC China to discover the latest developments and innovations across every aspect of Pharma and Biotech Equipment, Laboratory and Analytical techniques while experiencing the unique face-to-face networking opportunities that only Asia’s largest pharmaceutical networking event can provide.
Take your share of the growth in China’s pharma market.
Register for free at www.pmec-china.com
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERY
February 14th 2025Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering greater patient comfort and adherence to expand the therapeutic market.